TY - JOUR
T1 - Anesthesia and mitochondria
T2 - balancing toxicity and protection through emerging therapeutic strategies
AU - Zambrano, Kevin
AU - Castillo, Karina
AU - Maldonado, Giselle
AU - Fritzhand, Kevin
AU - Miranda, Leonidas S.
AU - Mujica, Luis
AU - Viera-Catota, Cynthia
AU - Castañeda, Verónica
AU - Vasconez, Henry C.
AU - Caicedo, Andrés
AU - Gavilanes, Antonio W.D.
N1 - Publisher Copyright:
© The Author(s) under exclusive licence to Japanese Society of Anesthesiologists 2025.
PY - 2025
Y1 - 2025
N2 - Anesthesia is a cornerstone of modern surgical practice, enabling interventions by deliberately modulating nociception and consciousness—from localized analgesia and mild sedation to deep unconsciousness. Yet the molecular and cellular mechanisms that produce these reversible states remain only partly defined, constraining our ability to predict interpatient variability, prevent mitochondrial- and neurotoxicity-related adverse effects, and optimize agent selection, dosing, and timing across perioperative care. Beyond their intended effects, anesthetics and their adjuvants impose substantial physiological stress on the brain, metabolism, and immune system, with particularly pronounced risks in vulnerable populations such as pediatric and elderly patients with developing and otherwise fragile neural networks. Recent studies have highlighted mitochondria, the cell’s energy processing unit and key regulator of homeostasis, as especially susceptible to anesthetic exposure. Evidence indicates that agents used in the perioperative period may disrupt mitochondrial function by altering oxidative phosphorylation, increasing reactive oxygen species (ROS) production, and impairing mitochondrial dynamics. Such disruptions can contribute to neurotoxicity, metabolic dysregulation, and immune suppression, potentially affecting postoperative recovery and long-term cognitive outcomes. This review critically examines emerging data on the interplay between anesthesia agents and mitochondrial function. We discuss the implications of mitochondrial dysfunction for neural health and postoperative recovery, and we highlight current and prospective strategies to possibly refine anesthesia drug protocols through targeted mitochondrial therapeutics. Ultimately, a deeper understanding of these mitochondrial interactions is imperative for developing safer, more effective anesthesia practices, especially for pediatric and other high-risk patient populations.
AB - Anesthesia is a cornerstone of modern surgical practice, enabling interventions by deliberately modulating nociception and consciousness—from localized analgesia and mild sedation to deep unconsciousness. Yet the molecular and cellular mechanisms that produce these reversible states remain only partly defined, constraining our ability to predict interpatient variability, prevent mitochondrial- and neurotoxicity-related adverse effects, and optimize agent selection, dosing, and timing across perioperative care. Beyond their intended effects, anesthetics and their adjuvants impose substantial physiological stress on the brain, metabolism, and immune system, with particularly pronounced risks in vulnerable populations such as pediatric and elderly patients with developing and otherwise fragile neural networks. Recent studies have highlighted mitochondria, the cell’s energy processing unit and key regulator of homeostasis, as especially susceptible to anesthetic exposure. Evidence indicates that agents used in the perioperative period may disrupt mitochondrial function by altering oxidative phosphorylation, increasing reactive oxygen species (ROS) production, and impairing mitochondrial dynamics. Such disruptions can contribute to neurotoxicity, metabolic dysregulation, and immune suppression, potentially affecting postoperative recovery and long-term cognitive outcomes. This review critically examines emerging data on the interplay between anesthesia agents and mitochondrial function. We discuss the implications of mitochondrial dysfunction for neural health and postoperative recovery, and we highlight current and prospective strategies to possibly refine anesthesia drug protocols through targeted mitochondrial therapeutics. Ultimately, a deeper understanding of these mitochondrial interactions is imperative for developing safer, more effective anesthesia practices, especially for pediatric and other high-risk patient populations.
KW - Anesthesia
KW - Immune suppression
KW - Intraoperative management
KW - Metabolic dysregulation
KW - Mitochondrial dysfunction
KW - Oxidative phosphorylation
KW - Pediatric anesthesia
KW - Preoperative assessment
KW - Reactive oxygen species (ROS)
UR - https://www.scopus.com/pages/publications/105017923491
U2 - 10.1007/s00540-025-03593-9
DO - 10.1007/s00540-025-03593-9
M3 - Review article
C2 - 41045340
AN - SCOPUS:105017923491
SN - 0913-8668
JO - Journal of Anesthesia
JF - Journal of Anesthesia
ER -